Literature DB >> 23518274

NICE's end of life decision making scheme: impact on population health.

Marissa Collins1, Nicholas Latimer.   

Abstract

Mesh：

Year:  2013        PMID： 23518274     DOI： 10.1136/bmj.f1363

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  19 in total

Review 1.  Market access of cancer drugs in European countries: improving resource allocation.

Authors:  Kim Pauwels; Isabelle Huys; Minne Casteels; Katelijne De Nys; Steven Simoens
Journal:  Target Oncol       Date:  2013-11-19       Impact factor: 4.493

2.  NICE's cost-effectiveness range: should it be lowered?

Authors:  J P Raftery
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

3.  Does the approach to economic evaluation in health care depend on culture, values, and institutional context?

Authors:  Aleksandra Torbica; Rosanna Tarricone; Michael Drummond
Journal:  Eur J Health Econ       Date:  2018-07

Review 4.  Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Authors:  Praveen Thokala; Jessica Ochalek; Ashley A Leech; Thaison Tong
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

5.  The New and Non-Transparent Cancer Drugs Fund.

Authors:  Eifiona M Wood; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

6.  Sustainability of costs of novel biologicals: Are we all heading for bankruptcy?

Authors:  Robert Likic
Journal:  Br J Clin Pharmacol       Date:  2020-04-15       Impact factor: 4.335

7.  The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial.

Authors:  David M Meads; Andrea Marshall; Claire T Hulme; Janet A Dunn; Hugo E R Ford
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

Review 8.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

9.  Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis.

Authors:  Vanessa Shih; Renske M Ten Ham; Christine T Bui; Dan N Tran; Jie Ting; Leslie Wilson
Journal:  J Skin Cancer       Date:  2015-06-10

Review 10.  Cost-effectiveness analysis in cardiac surgery: A review of its concepts and methodologies.

Authors:  Bart S Ferket; Jonathan M Oxman; Alexander Iribarne; Annetine C Gelijns; Alan J Moskowitz
Journal:  J Thorac Cardiovasc Surg       Date:  2017-11-15       Impact factor: 5.209
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.